Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

NRx Pharmaceuticals' Approach To Treating Depression And Suicide Ideation Brings Modern Solution To Centuries-Old Problem

By Meg Flippin Benzinga

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company’s lead program, NRX-101, is an oral, fixed-dose combination of D-cycloserine and lurasidone, which targets the brain’s NMDA receptor. 

Depression and suicide are centuries-old problems in need of modern-day treatments, and that’s what NRx believes it has with NRX-101 and NRX-100. Both drugs target the loss of neuroplasticity in the brain, which research has shown leads to depression and suicide ideation. 

“Suicidality is the loss of plasticity in the brain,” Javitt told Benzinga during the interview, noting that a loss of plasticity causes frequent depressive states and is associated with PTSD and suicide depression. “All of these drugs we are so excited about, whether it's Kentamine, which is NRX-100, or D-cycloserine, which is NRX-101, upregulate neuroplasticity. It causes the brain to make new connections.” 

NRX-100 just got Fast Track designation from the U.S. FDA  for the treatment of suicidal ideation in patients with depression. The drug already has that FDA designation for the treatment of suicidal bipolar depression. Javitt said the new designation takes its potential market from about 1 million to the 13 million U.S. adults the CDC says consider suicide each year. 

Outside of developing drugs to treat depression and suicide ideation, NRX is opening treatment clinics across the country through its HOPE Therapeutics subsidiary. 

Watch the full interview here: 
https://www.youtube.com/watch?v=AFNU5Jr7g7A

Featured image from Shutterstock.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

This content was originally published on Benzinga. Read further disclosures here.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.